Combination of Postoperative Adjuvant Chemoradiotherapy and Immune Checkpoint Inhibitors Significantly Prolongs Recurrence-Free Survival in Sinonasal Mucosal Melanoma

Read full text Summarise with VIRAT
Authors: Qiu-yue Ding, Junwan Wu, Ya Ding, Dandan Li, X J Wen, Hang Jiang, Linbin Chen, Qiong Zhang, Yuan Zhang, Lixia Lu, Xiaoshi Zhang, Jingjing Li
Cited by: 0
References: 33

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Importance The currently recommended postoperative adjuvant treatment for sinonasal mucosal melanoma (SNMM) (chemotherapy, optionally accompanied by local radiotherapy) has limited efficacy. Objective We aimed to provide a potentially optimal adjuvant therapeutic strategy for patients with SNMM. Design Retrospective cohort study. Setting Our hospital’s cancer center. Participants Seventy-nine patients with stage III/IV SNMM who underwent complete resection and received adjuvant radiotherapy between April 2012 and October 2022 were included in the study. Interventions Patients were categorized into 2 groups based on different adjuvant medical regimens: a temozolomide/dacarbazine-based chemotherapy group (n = 44) and a temozolomide/dacarbazine chemotherapy plus PD-1 inhibitor group (n = 35). Main outcome measures These included recurrence-free survival (RFS), distant metastasis-free survival (DMFS), failure patterns, and overall survival (OS). Results The median follow-up duration was 56.8 (8.85-104.75) months in the chemotherapy group and 27.7 (14.53-40.87) months in the chemotherapy plus PD-1 inhibitor group, respectively. Relative to adjuvant chemoradiotherapy, the combination of additional PD-1 inhibitor significantly prolonged RFS (mRFS: 10.0 months vs 18.9 months; HR, 0.43; 95% CI, 0.25-0.75; P = .002), DMFS (mDMFS: 11.2 months vs 18.9 months; HR, 0.48; 95% CI, 0.27-0.84; P = .009), and OS (29.1 months vs NA; HR, 0.36; 95% CI, 0.17-0.77; P = .006) in patients with SNMM. Within a 2-year timeframe, patients in the chemotherapy plus PD-1 inhibitor group exhibited a lower regional recurrence rate than those in the chemotherapy group (0.0% vs 18.8%, P < .001). The 2-year OS rates in the adjuvant chemotherapy group and the chemotherapy combined with PD-1 inhibitor group were 54.5% versus 75.7%, respectively, while the corresponding 4-year OS rates were 20.9% and 62.4%. Conclusions and relevance Surgery followed by adjuvant chemoradiotherapy and prompt initiation of PD-1 inhibitor therapy may improve local disease control in patients with SNMM.

Fields of Study & Subjects

Head and Neck Surgical Oncology Cutaneous Melanoma Detection and Management Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
Journal of Otolaryngology - Head and Neck Surgery
Volume
55
Pages
19160216251414150–19160216251414150
Publication date
1 March 2026
Language
EN